Nature biotechnology
-
The thinking behind the US Food and Drug Administration's (FDA) draft guidance on financial conflicts of interest for outside experts is deeply flawed.
The thinking behind the US Food and Drug Administration's (FDA) draft guidance on financial conflicts of interest for outside experts is deeply flawed.